teaser
Merck KGaA, Darmstadt, Germany, announced today that the American Academy of Neurology (AAN) has accepted a late-breaking abstract regarding cladribine tablets, its oral investigational treatment of multiple sclerosis, for an oral presentation at the AAN 61st Annual Meeting in Seattle.
The abstract is entitled “Results from the CLARITYa study: a phase III, randomised, double-blind study to evaluate the safety and efficacy of oral cladribine in relapsing-remitting multiple sclerosis”. The data is currently scheduled to be presented as a late-breaking oral presentation on April 29, 2009 by the study’s principal investigator, Dr Gavin Giovannoni, Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London, United Kingdom.
